Investorideas.com - Biotech Stocks; OTC Volume Leaders; Most Active ($1.00-$2.00): (OTCBB: SILA), (OTCBB: NNVC), (OTCBB: NEOP), (OTCBB: NWBO)

Investorideas.com - Biotech Stocks; OTC Volume Leaders; Most Active ($1.00-$2.00): (OTCBB: SILA), (OTCBB: NNVC), (OTCBB: NEOP), (OTCBB: NWBO)


Subscribe to Investor Ideas Newswire

Visit this company: www.otcvolumeleaders.com


Point Roberts, WA (Investorideas.com Newswire) July 26, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($1.00-$2.00) include Gold American Mining Corp. (OTCBB: SILA), NanoViricides, Inc. (OTCBB: NNVC), Neoprobe Corporation (OTCBB: NEOP), and Northwest Biotherapeutics Inc. (OTCBB: NWBO).


Sign up for Free OTC Volume Leader Alerts! http://bit.ly/otcvolumeleaders
OTC / Market Commentary:
Sectors include Biotech Stocks


One of the OTCBB volume leaders: Biotherapeutics Inc. (OTCBB: NWBO)"Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is focusing on development of its dendritic cell vaccines. The Company's lead clinical trial is a 240 patient double blind, randomized, placebo controlled Phase II trial in GBM. The trial remains open but is not currently enrolling patients. As part of the debt restructuring and ongoing fundraising activities, the Company expects to resume enrollment in this GBM trial later in the summer. The Company also received clearance from the FDA some time ago for a 600+ patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage."

Market Snapshot: (at time of release)
Dow 10,489.14 +64.52 +0.62%
Nasdaq 2,286.61 +17.14 +0.76%
S&P 500 1,111.69 +9.03 +0.82%
10 Yr Bond(%) 3.0180% +0.2400Oil 79.07 +0.09 +0.11% Gold 1,185.20 -2.50 -0.21%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.


OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!


OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/

Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.

Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp